Abbott’s D2E7 is Humira
Executive Summary
Abbott selects Humira as trade name for tumor necrosis factor inhibitor D2E7/adalimumab. Abbott submitted a BLA for rheumatoid arthritis April 2 and expects to launch in the first half of 2003. Humira will be the first product manufactured at Abbott's biotech plant in Barceloneta, Puerto Rico upon completion of the $350 mil. facility. Abbott also recently expanded its bioresearch center in Worcester, Mass. (1"The Pink Sheet" Oct. 14, p. 27)...